PA
RCKT icon

Perceptive Advisors’s Rocket Pharmaceuticals RCKT Stock Holding History

Perceptive Advisors’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-140,726
Closed -$939K – 103
2025
Q1 		$939K Sell
140,726
-237,858
-63% -$2.35M 0.03% 79
2024
Q4 		$4.76M Sell
378,584
-553,267
-59% -$8.33M 0.13% 72
2024
Q3 		$17.2M Sell
931,851
-314,746
-25% -$6.45M 0.36% 60
2024
Q2 		$26.8M Sell
1,246,597
-554,471
-31% -$12.7M 0.65% 47
2024
Q1 		$48.5M Buy
1,801,068
+93,670
+5% +$2.66M 0.85% 40
2023
Q4 		$51.2M Buy
1,707,398
+189,931
+13% +$4.19M 1.14% 27
2023
Q3 		$31.1M Buy
1,517,467
+349,104
+30% +$6.35M 1.04% 31
2023
Q2 		$23.2M Buy
1,168,363
+300,631
+35% +$6.07M 0.67% 45
2023
Q1 		$14.9M Sell
867,732
-210,472
-20% -$4.12M 0.44% 52
2022
Q4 		$21.1M Buy
1,078,204
+578,204
+116% +$10.6M 0.59% 41
2022
Q3 		$7.98M Sell
500,000
-666,883
-57% -$10.4M 0.23% 70
2022
Q2 		$16.1M Sell
1,166,883
-511,207
-30% -$6.09M 0.5% 45
2022
Q1 		$26.6M Sell
1,678,090
-281,035
-14% -$4.86M 0.53% 46
2021
Q4 		$42.8M Sell
1,959,125
-351,136
-15% -$9.58M 0.66% 39
2021
Q3 		$69.1M Sell
2,310,261
-441,342
-16% -$16.1M 1% 27
2021
Q2 		$122M Sell
2,751,603
-116,168
-4% -$5.05M 1.58% 16
2021
Q1 		$127M Sell
2,867,771
-529,096
-16% -$29.1M 1.61% 19
2020
Q4 		$186M Buy
3,396,867
+1,207,857
+55% +$44M 2% 11
2020
Q3 		$50M Hold
2,189,010
– – 0.73% 36
2020
Q2 		$45.8M Hold
2,189,010
– – 0.74% 34
2020
Q1 		$30.5M Sell
2,189,010
-50,231
-2% -$995K 0.8% 31
2019
Q4 		$51M Buy
2,239,241
+261,829
+13% +$4.37M 1.01% 22
2019
Q3 		$23M Hold
1,977,412
– – 0.62% 39
2019
Q2 		$29.7M Buy
1,977,412
+1,519,239
+332% +$26.5M 0.68% 38
2019
Q1 		$8.04M Buy
458,173
+218,000
+91% +$3.44M 0.23% 65
2018
Q4 		$3.5M Buy
+240,173
New +$3.99M 0.13% 68

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Perceptive Advisors's RCKT Position: Q2 2025 in Review

Perceptive Advisors sold out of Rocket Pharmaceuticals (RCKT) in Q2 2025, closing a stake of 140,726 shares — an estimated $939K sold.

Perceptive Advisors first reported a position in RCKT in Q4 2018 and held it in 26 quarters. The position peaked at $186M in Q4 2020. 196 funds tracked by Wall St. Rank hold RCKT as of Q2 2025.

  • Perceptive Advisors reported no remaining Rocket Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Perceptive Advisors sold 140,726 Rocket Pharmaceuticals shares in Q2 2025, an estimated $939K.
  • Perceptive Advisors first reported a position in Rocket Pharmaceuticals in Q4 2018 and held it in 26 quarters.
  • Perceptive Advisors's Rocket Pharmaceuticals position peaked at $186M in Q4 2020.
  • 196 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2025.

Based on Perceptive Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.